Glenn Nussdorf, a director at Organogenesis (NASDAQ:ORGO), sold 187,957 shares of the company’s stock on November 26, 2023. This transaction, executed at an average price of $5.29 per share, amounted to a total value of approximately $994,292.53. Following this sale, Nussdorf’s ownership in Organogenesis decreased by 6.36%, leaving him with 2,765,591 shares, valued at around $14,629,976.39.
The details of the sale were disclosed in a filing with the Securities and Exchange Commission (SEC), which is publicly accessible through their website.
Organogenesis Stock Performance
On the following day, shares of Organogenesis opened at $5.42. The company has experienced fluctuations in its stock price, having a one-year low of $2.61 and a high of $7.08. Current performance metrics indicate a 50-day simple moving average of $4.65 and a 200-day simple moving average of $4.28. Financially, Organogenesis shows a debt-to-equity ratio of 0.01, a current ratio of 3.32, and a quick ratio of 2.88. The company currently holds a market capitalization of $687.85 million and a price-to-earnings ratio of -45.17, with a beta of 1.68.
On November 6, 2023, Organogenesis released its quarterly earnings report, revealing an earnings per share (EPS) of $0.18, surpassing analysts’ expectations of $0.07 by $0.11. During the quarter, the company generated revenue of $150.86 million, exceeding the anticipated $134.10 million. In terms of profitability, Organogenesis reported a positive return on equity of 4.01%, although it did record a negative net margin of -1.30%. For fiscal year 2025, the company has set its earnings guidance at EPS, with analysts projecting an average EPS of -0.07 for the current fiscal year.
Institutional Investor Activity
Recent months have seen significant changes in institutional investments in Organogenesis. Notably, First Light Asset Management LLC acquired a new position valued at approximately $24.8 million in the second quarter. Additionally, Assenagon Asset Management S.A. increased its stake in Organogenesis by an impressive 748.1% during the same period, now holding 2,857,904 shares worth $10.46 million after acquiring an additional 2,520,941 shares.
Other notable investments include Driehaus Capital Management LLC, which purchased a new stake valued at about $7.76 million, and Invesco Ltd., which raised its stake by 779.7% in the first quarter, now owning 1,069,252 shares valued at $4.62 million. Vanguard Group Inc. also enhanced its position by 23.4%, now controlling 4,431,414 shares worth $19.14 million. Currently, institutional investors own approximately 49.57% of Organogenesis’ stock.
Organogenesis Holdings Inc. specializes in regenerative medicine, developing solutions for advanced wound care and surgical markets in the United States. Its product lineup includes innovative therapies such as Apligraf and Dermagraft, designed to enhance healing and recovery in patients.
This combination of executive sales, institutional activity, and positive earnings performance illustrates a dynamic environment at Organogenesis, highlighting both challenges and opportunities in the regenerative medicine sector.
